HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX

HALO raised its 2026 revenue guidance to $1.84-$1.91 billion while expanding its ENHANZE collaboration with ARGX, lifting the number of exclusive ENHANZE targets from six to eight.

The ARGX expansion adds two targets to the existing agreement. Terms include milestone payments and royalties on product sales, which gives HALO additional recurring revenue streams tied to ARGX's pipeline progress.

The guidance bump rests on royalty growth from two named products: JNJ's Darzalex and ARGX's Vyvgart Hytrulo. Both are partner-sold drugs, so HALO's top-line upside depends on partner commercial execution rather than its own sales force.

Interpretation: the combination of raised guidance and a wider ARGX deal signals that HALO's royalty model is scaling through existing relationships rather than relying on new partners. Two additional ARGX targets extend the runway for that royalty stream, though the source gives no payment amounts for the new milestones, so the near-term earnings effect is hard to size.

RHHBY is on the list of related names, but the source offers no specifics tying it to this announcement.